INS and cancer: There was a significant reduction in cancer mortality (sub)hazard for cumulative time exposure to premixed human (SHR 0.945, 95% CI 0.918–0.971, p = 0.001) and analogue insulins (SHR 0.962, 95% CI 0.935–0.990, p = 0.009), and for cumulative dose exposure to premixed human insulin (SHR 0.955, 95% CI 0.926–0.985, p = 0.004).